BioSpace News Archive

CooperCompanies announced that its Board of Directors has appointed Lawrence E. Kurzius as an independent director, effective December 1, 2023.

BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced it will host a virtual KOL Event on December 4, 2023 at 12:00 PM ET to discuss the positive topline results recently announced from Part 2 of Phase 1b/2a trial of BX004 in cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa (P. aeruginosa) infections.

AMN Healthcare (NYSE: AMN), the leader and innovator in total talent solutions for healthcare organizations across the United States, today announced it has closed on the acquisition of MSDR.

Variantyx, a leader in genomic precision medicine, announced that the set of short tandem repeat expansions detected by its Genomic Unity® line of whole genome-based tests has been expanded.

Cadrenal Therapeutics, Inc. announced that Quang Pham, CEO, will present at NobleCon19 - Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex, in Boca Raton, FL on Monday, December 4 at 4:00 p.m. Eastern time.

Johnson & Johnson announced that Eugene A. Woods, MBA, MHA, Chief Executive Officer of Advocate Health, has been appointed to its Board of Directors.

Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for BT-600, a drug/device combination for the treatment of moderate to severe ulcerative colitis.

Santé Ventures, an early-stage healthcare and life sciences investment firm, has announced the acquisition of its Fund III portfolio company, Laminar, Inc., by Johnson & Johnson Medtech.

Mithra announces that the US Food and Drug Administration has provided feedback regarding its new drug application marketing authorization filing in the United States.

Samsung Bioepis Co., Ltd. has signed a settlement and license agreement with Johnson & Johnson settling all pending US patent litigation between the two companies and clearing the way for commercialization of Samsung Bioepis’ SB17, a proposed biosimilar of reference medicine Stelara® in the United States.